Literature DB >> 10620182

PHEX gene and hypophosphatemia.

M K Drezner1.   

Abstract

PHEX gene and hypophosphatemia. X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) are diseases that have in common abnormal proximal renal tubular function resulting in increased renal clearance of inorganic phosphorus and hypophosphatemia. The recent discovery of the PHEX gene has provided new insights to these disorders. In this regard, identification of the PHEX gene product as a membrane-bound endopeptidase suggests that the pathophysiologic cascade underlying XLH likely involves inactivation mutations of the gene causing a failure to clear an active hormone, phosphatonin, from the circulation. The presence of this hormone through unknown mechanisms decreases the sodium-dependent phosphate cotransporter in the kidney, resulting in impaired phosphate transport. In contrast, TIO likely evolves secondary to tumor overproduction of the putative phosphatonin, which exerts physiologic function despite efforts to counteract the resultant hypophosphatemia with overproduction of PHEX transcripts that are insufficient to accommodate the enhanced substrate load. These potential pathophysiologic mechanisms for XLH and TIO provide valuable inroads to understanding phosphate homeostasis, as well as vitamin D metabolism, bone mineralization, and calcium metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620182     DOI: 10.1046/j.1523-1755.2000.00807.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

1.  Ablation of systemic phosphate-regulating gene fibroblast growth factor 23 (Fgf23) compromises the dentoalveolar complex.

Authors:  E Y Chu; H Fong; F A Blethen; K A Tompkins; B L Foster; K D Yeh; K J Nagatomo; D Matsa-Dunn; D Sitara; B Lanske; R B Rutherford; M J Somerman
Journal:  Anat Rec (Hoboken)       Date:  2010-07       Impact factor: 2.064

Review 2.  The genetic and molecular bases of monogenic disorders affecting proteolytic systems.

Authors:  I Richard
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

3.  Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues.

Authors:  Ryan P Downs; Zhousheng Xiao; Munachi O Ikedionwu; Jacob W Cleveland; Ai Lin Chin; Abigail E Cafferty; L Darryl Quarles; Jesse D Carrick
Journal:  Bioorg Med Chem       Date:  2020-11-18       Impact factor: 3.641

4.  MRNA expression of Phex in mice and rats: the effect of low phosphate diet.

Authors:  M H Meyer; R A Meyer
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.633

5.  Effect of polyamine depletion on caspase activation: a study with spermine synthase-deficient cells.

Authors:  C Stefanelli; C Pignatti; B Tantini; M Fattori; I Stanic; C A Mackintosh; F Flamigni; C Guarnieri; C M Caldarera; A E Pegg
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

6.  Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.

Authors:  Peter S N Rowe; Naoko Matsumoto; Oak D Jo; Remi N J Shih; Jeannine Oconnor; Martine P Roudier; Steve Bain; Shiguang Liu; Jody Harrison; Norimoto Yanagawa
Journal:  Bone       Date:  2006-06-09       Impact factor: 4.398

7.  FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation.

Authors:  Sangeeta Pande; Cynthia S Ritter; Marcos Rothstein; Karen Wiesen; John Vassiliadis; Rajiv Kumar; Susan C Schiavi; Eduardo Slatapolsky; Alex J Brown
Journal:  Nephron Physiol       Date:  2006-05-10

8.  Hyperostosis with hyperphosphatemia and tumoral calcinosis: a case report.

Authors:  Hasan Otukesh; Rozita Hoseini; Hamid Chalian; Majid Chalian; Amir Ebrahim Safarzadeh; Marjan Shakiba; Ali Poorian
Journal:  Pediatr Nephrol       Date:  2007-04-17       Impact factor: 3.714

9.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

10.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Makoto Kakitani; Yuji Yamazaki; Hisashi Hasegawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Kazuma Tomizuka; Takeyoshi Yamashita
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.